PT-141 (Bremelanotide) | Peptide Encyclopedia | Auryx
PT-141 (Bremelanotide) is a physician-reviewed Auryx Learn encyclopedia entry. A melanocortin receptor agonist that increases sexual desire and arousal in both men and women through central nervous system activation. This page is educational. It is not a dosing guide and not a substitute for a licensed clinician.
How it works
PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus — the brain's arousal center — triggering the neurological cascade of sexual desire without relying on vascular mechanisms. This makes it effective in both sexes and in individuals where PDE5 inhibitors (e.g., Viagra) have limited effect.
- Increased libido and sexual desire in men and women
- Enhanced arousal independent of vascular function
- Rapid onset (1–4 hours after administration)
- Does not interact with cardiovascular system the way PDE5 inhibitors do
Used for hypoactive sexual desire disorder and arousal difficulties in both sexes. Particularly valuable when other approaches have failed.
Subject of multiple Phase 2 and Phase 3 clinical trials examining central melanocortin receptor agonism and its downstream effects on arousal neurocircuitry in both sexes.
Clinic context and next steps
Pair this entry with the matching shop listing when Auryx offers the compound, or browse the full encyclopedia. Category shopping lives under shop. Mechanism language is not a personal outcome and does not approve a protocol.
Auryx is an MD-led telemedicine clinic. Eligible patients complete remote intake; compounds ship from regulated United States compounding pharmacies after clinical review. Use the protocol finder if you are matching a goal, our method for the four-step process, and about for physician leadership. Citations sit on sources. Questions go to contact or info@auryxlife.com.
Nothing on Learn diagnoses, treats, cures, or prevents disease. Read privacy and terms before you share health information. Language homepages: español and português.